P Roy Vagelos Sells 74,710 Shares of Regeneron Pharmaceuticals Inc (REGN) Stock

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Chairman P Roy Vagelos sold 74,710 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, June 21st. The shares were sold at an average price of $327.87, for a total value of $24,495,167.70. Following the completion of the transaction, the chairman now owns 553,121 shares of the company’s stock, valued at $181,351,782.27. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of Regeneron Pharmaceuticals traded up $3.65, reaching $332.69, during midday trading on Friday, according to Marketbeat.com. The stock had a trading volume of 38,794 shares, compared to its average volume of 720,315. Regeneron Pharmaceuticals Inc has a 12-month low of $281.89 and a 12-month high of $543.55. The company has a current ratio of 3.59, a quick ratio of 2.94 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $36.29 billion, a P/E ratio of 24.82, a PEG ratio of 1.21 and a beta of 1.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, May 3rd. The biopharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.08 by ($0.41). Regeneron Pharmaceuticals had a return on equity of 29.92% and a net margin of 23.54%. The firm had revenue of $1.51 billion during the quarter, compared to analysts’ expectations of $1.50 billion. During the same quarter in the previous year, the company posted $2.92 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 14.6% compared to the same quarter last year. equities research analysts predict that Regeneron Pharmaceuticals Inc will post 17.2 EPS for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Loomis Sayles & Co. L P boosted its holdings in shares of Regeneron Pharmaceuticals by 34.2% in the 1st quarter. Loomis Sayles & Co. L P now owns 2,819,755 shares of the biopharmaceutical company’s stock worth $971,011,000 after purchasing an additional 718,144 shares in the last quarter. Polen Capital Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 2.1% in the 1st quarter. Polen Capital Management LLC now owns 1,419,141 shares of the biopharmaceutical company’s stock worth $488,695,000 after purchasing an additional 29,596 shares in the last quarter. Sustainable Growth Advisers LP boosted its holdings in shares of Regeneron Pharmaceuticals by 18.6% in the 1st quarter. Sustainable Growth Advisers LP now owns 1,045,910 shares of the biopharmaceutical company’s stock worth $360,169,000 after purchasing an additional 163,981 shares in the last quarter. American Century Companies Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 9.1% in the 1st quarter. American Century Companies Inc. now owns 957,189 shares of the biopharmaceutical company’s stock worth $329,618,000 after purchasing an additional 79,602 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 3.6% in the 4th quarter. Geode Capital Management LLC now owns 880,481 shares of the biopharmaceutical company’s stock worth $330,385,000 after purchasing an additional 30,581 shares in the last quarter. Hedge funds and other institutional investors own 66.22% of the company’s stock.

REGN has been the subject of several recent research reports. BidaskClub upgraded Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, March 29th. Barclays set a $290.00 price target on Regeneron Pharmaceuticals and gave the company a “sell” rating in a research report on Thursday, May 3rd. Credit Suisse Group set a $420.00 price target on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, April 27th. Zacks Investment Research cut Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 9th. Finally, BMO Capital Markets set a $361.00 price target on Regeneron Pharmaceuticals and gave the company a “hold” rating in a research report on Friday, May 4th. Four research analysts have rated the stock with a sell rating, sixteen have given a hold rating and eight have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $426.88.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Insider Buying and Selling by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply